Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Idiopathic Focal Segmental Glomerulosclerosis”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Not applicableStudy completedNCT03126201
What this trial is testing

Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis

Who this might be right for
GlomerulonephritisFocal Segmental Glomerulosclerosis
Istanbul University 86
Large-scale testing (Phase 3)UnknownNCT03298698
What this trial is testing

Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome

Who this might be right for
Idiopathic Nephrotic SyndromeMinimal Change DiseaseFocal Segmental Glomerulosclerosis
Radboud University Medical Center 40
Testing effectiveness (Phase 2)Study completedNCT02921789
What this trial is testing

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Who this might be right for
Kidney TransplantationPrimary Focal Segmental Glomerulosclerosis (FSGS)
Astellas Pharma Global Development, Inc. 67
Not applicableStudy completedNCT00255398
What this trial is testing

Kidney Disease Biomarkers

Who this might be right for
Kidney DiseaseGlomerular DiseaseIdiopathic Nephrotic Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 25
Not applicableLooking for participantsNCT04924712
What this trial is testing

INS, B Cells and Microbiota

Who this might be right for
MicrobiotaB-lymphocytesGlomerulosclerosis+1 more
Nantes University Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03649152
What this trial is testing

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

Who this might be right for
Focal Segmental Glomerulosclerosis
Dimerix Bioscience Pty Ltd 8
Large-scale testing (Phase 3)Study completedNCT03493685
What this trial is testing

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. 371
Post-approval studies (Phase 4)Study completedNCT01155141
What this trial is testing

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

Who this might be right for
Kidney Diseases
Stanford University 15
Not applicableNot Yet RecruitingNCT06315504
What this trial is testing

Circulating Factors in Nephrotic Syndrome

Who this might be right for
Nephrotic SyndromeMembranous NephropathyMinimal Change Disease+1 more
Iain Bressendorff 104
Early research (Phase 1)Study completedNCT00193648
What this trial is testing

Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Glomerulosclerosis
Northwell Health 21
Testing effectiveness (Phase 2)Study completedNCT04983888
What this trial is testing

Obinutuzumab in Primary FSGS

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Mayo Clinic 20
Not applicableStudy completedNCT07702981
What this trial is testing

Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome

Who this might be right for
Membranous NephropathyMinimal Change Disease (MCD)Focal Segmental Glomerulosclerosis (FSGS)
University Hospital, Ioannina 40
Testing effectiveness (Phase 2)Study completedNCT01665391
What this trial is testing

Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Genzyme, a Sanofi Company 36
Testing effectiveness (Phase 2)Study completedNCT01573533
What this trial is testing

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Mayo Clinic 9
Large-scale testing (Phase 3)UnknownNCT02896270
What this trial is testing

Valproic Acid for Idiopathic Nephrotic Syndrome

Who this might be right for
Idiopathic Nephrotic SyndromeFocal Segmental GlomerulosclerosisMinimal Change Disease
Universitair Ziekenhuis Brussel 15
Testing effectiveness (Phase 2)Ended earlyNCT05441826
What this trial is testing

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Minimal Change DiseaseFocal Segmental Glomerulosclerosis
Tenet Medicines 1
Large-scale testing (Phase 3)Active Not RecruitingNCT06635720
What this trial is testing

REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)

Who this might be right for
Nephrotic Syndrome in ChildrenNephrotic Syndrome, Minimal ChangeNephrotic Syndrome+1 more
The Hospital for Sick Children 50
Early research (Phase 1)UnknownNCT02382874
What this trial is testing

Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)

Who this might be right for
Focal Segmental Glomerulosclerosis
Royan Institute 5
Testing effectiveness (Phase 2)Ended earlyNCT03703908
What this trial is testing

CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

Who this might be right for
Focal Segmental Glomerulosclerosis
Amgen 5
Testing effectiveness (Phase 2)Study completedNCT02000440
What this trial is testing

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Glomerulosclerosis, Focal Segmental
GlaxoSmithKline 17
Next Page